Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: J Mol Cell Cardiol. 2009 Nov 13;48(2):367. doi: 10.1016/j.yjmcc.2009.11.003

Fig. 2.

Fig. 2

Cardiomyocyte contractile properties in FVB and MT transgenic mice treated with or without LPS (4 and 40 mg/kg, i.p.). A: Resting cell length; B: Peak shortening (PS, normalized to cell length); C: Maximal velocity of shortening (+ dL/dt); D: Maximal velocity of relengthening (− dL/dt); E: Time-to-PS (TPS); and F: Time-to-90% relengthening (TR90). Mean ± SEM, n = 85–87 cells from 4 mice per group, * p < 0.05 vs. FVB group; # p < 0.05 vs. respective FVB-LPS group.